VTE Risk High in Cancer Patients Receiving Immune Checkpoint Inhibitors
History of VTE predicts VTE occurrence; VTE occurrence linked to increased mortality
Renal Cell Carcinoma
Local Salvage Therapy Effective for Local, Regional Recurrence of RCC
Local surgery or ablation may be most appropriate for patients with a solitary site of locoregional recurrence following definitive surgery for clinically localized renal cell carcinoma, according to investigators.
Pembrolizumab Plus Lenvatinib Prolongs Survival in Renal Cell Carcinoma
Investigators report findings from the phase 3 CLEAR trial that assessed outcomes with pembrolizumab plus lenvatinib, lenvatinib plus everolimus, or sunitinib in treatment-naive patients with advanced renal cell carcinoma.
Cutaneous AEs Linked to Immune Checkpoint Inhibitor Therapy
Cutaneous immune-related adverse events seen in 25% of cancer patients initiating ICI therapy with median onset time of 113 days
Renal Hypothermia During PN Fails to Preserve Kidney Function
A study of the effect of renal hypothermia during partial nephrectomy should have an immediate impact on surgical practice, according to investigators.
Factors Associated With Response to Nivolumab in Renal Cell Carcinoma
A study was conducted to assess factors contributing to response to nivolumab treatment for advanced clear cell renal cell carcinoma.
Fotivda Now Available for Renal Cell Carcinoma
Fotivda is an oral vascular endothelial growth factor tyrosine kinase inhibitor.
Belzutifan Gets Priority Review for Von Hippel-Lindau Disease-Associated RCC
Belzutifan is a potent and selective inhibitor of HIF-2α.
Fotivda Approved for Relapsed/Refractory Advanced Renal Cell Carcinoma
The approval was based on data from a phase 3 TIVO-3 study that compared tivozanib to sorafenib in adults with relapsed or refractory advanced RCC after 2 or more prior systemic therapies.
Nivolumab Plus Cabozantinib Tops Sunitinib for Renal Cell Carcinoma
Combination therapy superior with respect to progression-free, overall survival and overall response for first-line treatment of advanced RCC
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...